Andrew Jones summarises a large Finnish population-based cohort study, which finds that childhood adversities strongly predict the use of psychotropic drugs (such as antidepressants and antipsychotics) in adulthood.
[read the full story...]
Jennifer Laidlaw writes her debut blog on a recent RCT in JAMA about collaborative care for adolescent depression in primary care. The trial concludes that collaborative care is both feasible and effective in improving outcomes, but Jennifer highlights a number of limitations and questions for future research.
[read the full story...]
Helge Hasselman summarises a Cochrane review of tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents, which finds low quality evidence and no justification for prescribing these drugs in this group of patients.
[read the full story...]
Andrew Shepherd reviews the recent controversial BMJ study that suggests the FDA black box warning about antidepressant use in young people, may have inadvertently caused an increase in suicidal behaviour. He finds it’s not quite that clear cut.
[read the full story...]
Major depressive disorder (MDD) is unfortunately a relatively common condition in children and adolescents. Depression is estimated to affect 2% of pre-pubertal children and 5-8% of adolescents (Son et al, 2000). As you might expect, depression has a significant negative impact on the development, functioning and risk for suicide in individuals affected, as well as [read the full story…]
Clinical depression is one of the most common mental health problems occurring in children and adolescents. It is often accompanied or followed by additional negative outcomes, including social and academic problems, anxiety and substance use. Many depressed adolescents continue to have recurring problems throughout adulthood. A variety of antidepressant drugs, such as tricyclics and selective [read the full story…]
Selective serotonin reuptake inhibitors (SSRIs) have long been suspected to – paradoxically- increase suicidal behaviour in adolescent and pediatric patients. Consequently, national watchdogs started issuing black label warnings for all SSRIs to educate physicians and patients about associated risks. While clearly curbing the amount of antidepressant prescriptions, concerns have been voiced that this step has [read the full story…]
Much of the research about depression in children and adolescents focuses on how to treat the illness during the acute phase. This review from the Cochrane Depression, Anxiety and Neurosis Review Group is more concerned with the ways in which interventions can be used to prevent relapse or recurrence of depressive disorders. The review looks specifically at two [read the full story…]
Young people with autism spectrum disorders (ASD) are usually given some kind of behavioural or educational intervention to help improve their overall functioning. However, in some cases, those individuals who have high levels of repetitive, obsessive-compulsive type behaviours and mood disorders are treated with drug interventions, although there is little high quality evidence to support [read the full story…]
In 2004 the US Food and Drug Administration published a “black box” warning that highlighted an increased risk of suicide and suicidal thoughts in young people who were taking antidepressants. This warning was updated in 2007. A new analysis of 41 randomised controlled trials has been published in the Archives of General Psychiatry, which suggests [read the full story…]
